Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment.

Gutting T, Schulte N, Belle S, Betge J, Härtel N, Wilke J, Weers J, Ebert MP, Zhan T.

J Gastrointestin Liver Dis. 2019 Dec 9;28(4):503-507. doi: 10.15403/jgld-397.

2.

Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.

Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, Betge J, Härtel N, Kather JN, Weis CA, Gaiser T, Marx A, Weiss C, Hofheinz R, Miller IS, Loupakis F, Lenz HJ, Byrne AT, Ebert MP.

EBioMedicine. 2019 Jul;45:139-154. doi: 10.1016/j.ebiom.2019.07.004. Epub 2019 Jul 9.

3.

Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing.

Herrmann S, Zhan T, Betge J, Rauscher B, Belle S, Gutting T, Schulte N, Jesenofsky R, Härtel N, Gaiser T, Hofheinz RD, Ebert MP, Boutros M.

Mol Oncol. 2019 Aug;13(8):1669-1683. doi: 10.1002/1878-0261.12539. Epub 2019 Jul 19.

4.

Analysis of the Course of Chronic Pancreatitis: Pancreatic Burnout Rates Are Only Increased in a Subgroup of Patients With Alcoholic Chronic Pancreatitis.

Hirth M, Weiss C, Hardt P, Gubergrits N, Härtel N, Ebert MP, Schneider A.

Pancreas. 2019 May/Jun;48(5):726-733. doi: 10.1097/MPA.0000000000001302.

PMID:
31091222
5.

Management of immune related adverse events induced by immune checkpoint inhibition.

Teufel A, Zhan T, Härtel N, Bornschein J, Ebert MP, Schulte N.

Cancer Lett. 2019 Aug 1;456:80-87. doi: 10.1016/j.canlet.2019.04.018. Epub 2019 Apr 30.

PMID:
31051213
6.

Clinical Course of Chronic Pancreatitis in Elderly Patients.

Hirth M, Härtel N, Weiss C, Hardt P, Gubergrits N, Ebert MP, Schneider A.

Digestion. 2019;100(3):152-159. doi: 10.1159/000494349. Epub 2019 Jan 10.

PMID:
30630169
7.

Endogenous Cell Type-Specific Disrupted in Schizophrenia 1 Interactomes Reveal Protein Networks Associated With Neurodevelopmental Disorders.

Wilkinson B, Evgrafov OV, Zheng D, Hartel N, Knowles JA, Graham NA, Ichida JK, Coba MP.

Biol Psychiatry. 2019 Feb 15;85(4):305-316. doi: 10.1016/j.biopsych.2018.05.009. Epub 2018 May 23.

8.

Checkpoints and beyond - Immunotherapy in colorectal cancer.

Gutting T, Burgermeister E, Härtel N, Ebert MP.

Semin Cancer Biol. 2019 Apr;55:78-89. doi: 10.1016/j.semcancer.2018.04.003. Epub 2018 Apr 30. Review.

PMID:
29716829
9.

Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer.

Burgermeister E, Höde P, Betge J, Gutting T, Merkel A, Wu W, Tänzer M, Mossner M, Nowak D, Magdeburg J, Rückert F, Sticht C, Breitkopf-Heinlein K, Schulte N, Härtel N, Belle S, Post S, Gaiser T, Heppner BI, Behrens HM, Röcken C, Ebert MPA.

Oncotarget. 2017 Sep 15;8(49):84714-84728. doi: 10.18632/oncotarget.20950. eCollection 2017 Oct 17.

10.

Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.

Betge J, Barat A, Murphy V, Hielscher T, Van Grieken NC, Belle S, Zhan T, Härtel N, Kripp M, Bacon O, Cordes M, Kay EW, Verheul HM, Neerincx M, Hennessy B, Hofheinz RD, Gaiser T, Ylstra B, Prehn JH, Lambrechts D, Byrne AT, Ebert MP, Schulte N.

Digestion. 2016;94(3):129-137. doi: 10.1159/000449412. Epub 2016 Oct 19.

PMID:
27756074
11.

Gastric Cancer: New Drugs - New Strategies.

Schulte N, Ebert MP, Härtel N.

Gastrointest Tumors. 2014 May;1(4):180-94. doi: 10.1159/000380786. Epub 2015 Mar 27. Review.

12.

Hodgkin's lymphoma in a patient with cystic fibrosis: a clinical challenge.

Baumann S, Kuchler F, Reinwald M, Tenenbaum T, Härtel N, Hofmann WK, Buchheidt D.

Ann Hematol. 2013 Apr;92(4):571-2. doi: 10.1007/s00277-012-1613-0. Epub 2012 Nov 1. No abstract available.

PMID:
23114749
13.

Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.

Klag T, Härtel N, Erben P, Schwaab J, Schnetzke U, Schenk T, Hochhaus A, La Rosée P.

Leukemia. 2012 Jun;26(6):1321-8. doi: 10.1038/leu.2011.380. Epub 2012 Jan 13.

PMID:
22289991
14.

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.

Härtel N, Klag T, Hanfstein B, Mueller MC, Schenk T, Erben P, Hochhaus A, La Rosée P.

J Cancer Res Clin Oncol. 2012 Feb;138(2):203-12. doi: 10.1007/s00432-011-1086-x. Epub 2011 Nov 17.

PMID:
22089930
15.

Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.

La Rosée P, Holm-Eriksen S, Konig H, Härtel N, Ernst T, Debatin J, Mueller MC, Erben P, Binckebanck A, Wunderle L, Shou Y, Dugan M, Hehlmann R, Ottmann OG, Hochhaus A.

Haematologica. 2008 May;93(5):765-9. doi: 10.3324/haematol.12186. Epub 2008 Mar 26.

16.

Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.

Konig H, Härtel N, Schultheis B, Schatz M, Lorentz C, Melo JV, Hehlmann R, Hochhaus A, La Rosée P.

Haematologica. 2007 Jun;92(6):838-41.

17.

Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.

La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW.

Clin Cancer Res. 2006 Nov 1;12(21):6540-6.

Supplemental Content

Loading ...
Support Center